Voyager Therapeutics (NASDAQ:VYGR) Upgraded to Hold at Wall Street Zen

Voyager Therapeutics (NASDAQ:VYGR) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Voyager Therapeutics Stock Performance

Shares of VYGR stock opened at $4.45 on Friday. The stock has a 50 day moving average price of $3.92 and a 200 day moving average price of $4.17. Voyager Therapeutics has a 52-week low of $2.64 and a 52-week high of $5.55. The firm has a market capitalization of $265.22 million, a P/E ratio of -2.19 and a beta of 1.32.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Monday, March 9th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.08. Voyager Therapeutics had a negative return on equity of 51.35% and a negative net margin of 296.53%.The company had revenue of $13.46 million for the quarter, compared to the consensus estimate of $10.49 million. As a group, sell-side analysts forecast that Voyager Therapeutics will post -0.91 EPS for the current year.

Insider Buying and Selling

In related news, CEO Alfred Sandrock sold 14,197 shares of the firm’s stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $3.79, for a total value of $53,806.63. Following the transaction, the chief executive officer owned 484,060 shares of the company’s stock, valued at $1,834,587.40. This trade represents a 2.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last quarter, insiders have sold 49,783 shares of company stock valued at $188,694. Company insiders own 6.39% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

Large investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC increased its position in shares of Voyager Therapeutics by 179.3% during the first quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock worth $1,674,000 after acquiring an additional 317,927 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in shares of Voyager Therapeutics during the first quarter valued at approximately $218,000. Acadian Asset Management LLC boosted its holdings in shares of Voyager Therapeutics by 863.3% in the first quarter. Acadian Asset Management LLC now owns 230,708 shares of the company’s stock valued at $778,000 after purchasing an additional 206,758 shares during the period. Bank of Montreal Can bought a new position in Voyager Therapeutics in the second quarter worth approximately $36,000. Finally, Los Angeles Capital Management LLC bought a new position in Voyager Therapeutics in the second quarter worth approximately $50,000. 48.03% of the stock is owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.